title: Management of Malignant Peritoneal Mesothelioma Using Cytoreductive Surgery and Perioperative Chemotherapy.
abstract: Malignant peritoneal mesothelioma is a rare disease, with approximately 800 new patients per year in the United States. Its natural history is defined by progression restricted to the peritoneal space. In the past, patients with this disease had a limited lifespan of approximately 1 year. Numerous single-institution studies as well as a systematic review have reported median survival of 3 to 5 years with a combination of cytoreductive surgery and hyperthermic perioperative chemotherapy. These markedly improved survival statistics were achieved in experienced centers with 1% mortality and 20% morbidity rates. Data have shown that knowledgeable patient selection is required to prevent patients unlikely to benefit from undergoing these interventions. The conclusion is that patients with peritoneal mesothelioma can experience long-term progression-free survival or significant palliation with cytoreductive surgery plus hyperthermic perioperative chemotherapy. This management plan should be considered the standard of care for properly selected patients with malignant peritoneal mesothelioma at experienced centers around the world.
authors.affiliation: MedStar Washington Hospital Center, Washington, DC; University of Chicago, Chicago, IL; University of Maryland School of Medicine, Baltimore, MD; Mesothelioma Applied Research Foundation, Alexandria, VA; and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
authors.forename: Paul H
authors.initials: PH
authors.lastname: Sugarbaker
authors.affiliation: MedStar Washington Hospital Center, Washington, DC; University of Chicago, Chicago, IL; University of Maryland School of Medicine, Baltimore, MD; Mesothelioma Applied Research Foundation, Alexandria, VA; and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
authors.forename: Kiran K
authors.initials: KK
authors.lastname: Turaga
authors.affiliation: MedStar Washington Hospital Center, Washington, DC; University of Chicago, Chicago, IL; University of Maryland School of Medicine, Baltimore, MD; Mesothelioma Applied Research Foundation, Alexandria, VA; and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
authors.forename: H Richard
authors.initials: HR
authors.lastname: Alexander
authors.affiliation: MedStar Washington Hospital Center, Washington, DC; University of Chicago, Chicago, IL; University of Maryland School of Medicine, Baltimore, MD; Mesothelioma Applied Research Foundation, Alexandria, VA; and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
authors.forename: Marcello
authors.initials: M
authors.lastname: Deraco
authors.affiliation: MedStar Washington Hospital Center, Washington, DC; University of Chicago, Chicago, IL; University of Maryland School of Medicine, Baltimore, MD; Mesothelioma Applied Research Foundation, Alexandria, VA; and Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori di Milano, Milan, Italy.
authors.forename: Mary
authors.initials: M
authors.lastname: Hesdorffer
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D065426:Cytoreduction Surgical Procedures / Q000009:adverse effects; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D008654:Mesothelioma / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*; D000086002:Mesothelioma, Malignant; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000601:surgery; D019990:Perioperative Care; D010534:Peritoneal Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000601:surgery*
chemical_list: D000970:Antineoplastic Agents